- Home
- MNPR vs IMUX Comparison
MNPR vs IMUX Comparison
Compare MNPR & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNPR
- IMUX
- Stock Information
- Founded
- MNPR 2014
- IMUX 2016
- Country
- MNPR United States
- IMUX United States
- Employees
- MNPR N/A
- IMUX N/A
- Industry
- MNPR Biotechnology: Pharmaceutical Preparations
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- MNPR Health Care
- IMUX Health Care
- Exchange
- MNPR Nasdaq
- IMUX Nasdaq
- Market Cap
- MNPR 113.5M
- IMUX 100.0M
- IPO Year
- MNPR 2019
- IMUX N/A
- Fundamental
- Price
- MNPR $28.54
- IMUX $0.95
- Analyst Decision
- MNPR Strong Buy
- IMUX Strong Buy
- Analyst Count
- MNPR 4
- IMUX 6
- Target Price
- MNPR $38.50
- IMUX $12.67
- AVG Volume (30 Days)
- MNPR 59.4K
- IMUX 991.0K
- Earning Date
- MNPR 11-08-2024
- IMUX 02-20-2025
- Dividend Yield
- MNPR N/A
- IMUX N/A
- EPS Growth
- MNPR N/A
- IMUX N/A
- EPS
- MNPR N/A
- IMUX N/A
- Revenue
- MNPR N/A
- IMUX N/A
- Revenue This Year
- MNPR N/A
- IMUX N/A
- Revenue Next Year
- MNPR N/A
- IMUX N/A
- P/E Ratio
- MNPR N/A
- IMUX N/A
- Revenue Growth
- MNPR N/A
- IMUX N/A
- 52 Week Low
- MNPR $1.55
- IMUX $0.95
- 52 Week High
- MNPR $38.50
- IMUX $2.11
- Technical
- Relative Strength Index (RSI)
- MNPR 60.16
- IMUX 36.31
- Support Level
- MNPR $24.00
- IMUX $0.99
- Resistance Level
- MNPR $26.52
- IMUX $1.05
- Average True Range (ATR)
- MNPR 2.42
- IMUX 0.07
- MACD
- MNPR 0.32
- IMUX -0.00
- Stochastic Oscillator
- MNPR 68.85
- IMUX 1.50
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.